The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Ludvig Svensson, Penser Access by Carnegie, Tel: +46 8 463 80 00. Penser Access by Carnegie

  Quarterly Report 3 24/25, June 25, 2025

As we move into the second half of 2025, our preparations for the anticipated Phase 3 readout of DIAGNODE-3 continue at full pace, reinforced by a solid financial base, an expanding organization, and robust progress across all operational fronts.

In a capital market marked by cautious investor sentiment, Diamyd Medical has secured significant new funding under exceptionally favorable conditions. The recently completed...

As we count down the months to the pivotal Phase 3 readout, our conviction grows stronger that Diamyd® may become the first precision immunotherapy approved for Type 1 Diabetes.
Ulf Hannelius, President and CEO

Calendar

  
September 15 − September 19, 2025
EASD 61st Annual meeting
October 8, 2025
Year-end Report
Year-end Report 2024/2025
November 13, 2025
Annual Report
Annual Report 2025
December 4, 2025
Annual General Meeting
Annual General Meeting 2025
 

Diamyd Medical

Developing precision medicine therapies for the prevention and treatment of autoimmune diabetes

 

Ten largest shareholders as of June 30, 2025

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 16 830 376 12.24 9.96
Lindkvist, Bertil 8 925 000 6.49 5.28
Nordnet Pension 7 682 064 5.59 4.54
Essen-Möller, Anders * 1 135 620 3 219 040 3.17 8.62
Nordica Life 2 312 500 1.68 1.37
Essen-Möller, Maria-Teresa 400 000 963 998 0.99 2.94
Pictet and CIE (Eureope), Succurs, Ale de Lux 1 250 000 0.91 0.74
SEB Life International Insurance 1 046 901 0.76 0.62
Möller, Vidar 1 029 420 0.75 0.61
Konstruktions o Försäljningsaktiebolag 906 250 0.66 0.54
Remaining shareholders 1 967 500 89 831 054 66.76 64.79
Total 3 503 120 133 996 603 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS